RT Journal Article
SR Electronic
T1 Efficient Neutralization of SARS-CoV-2 Omicron and Other VOCs by a Broad Spectrum Antibody 8G3
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2022.02.25.482049
DO 10.1101/2022.02.25.482049
A1 Hang Ma
A1 Chien-Te K. Tseng
A1 Huifang Zong
A1 Yunji Liao
A1 Yong Ke
A1 Haoneng Tang
A1 Lei Wang
A1 Zhenyu Wang
A1 Yang He
A1 Yunsong Chang
A1 Shusheng Wang
A1 Aleksandra Drelich
A1 Jason Hsu
A1 Vivian Tat
A1 Yunsheng Yuan
A1 Mingyuan Wu
A1 Junjun Liu
A1 Yali Yue
A1 Wenbo Xu
A1 Xiaoju Zhang
A1 Ziqi Wang
A1 Li Yang
A1 Hua Chen
A1 Yanlin Bian
A1 Baohong Zhang
A1 Haiyang Yin
A1 Yi Chen
A1 En Zhang
A1 Xiaoxiao Zhang
A1 John Gilly
A1 Tao Sun
A1 Lei Han
A1 Yueqing Xie
A1 Hua Jiang
A1 Jianwei Zhu
YR 2022
UL http://biorxiv.org/content/early/2022/03/03/2022.02.25.482049.abstract
AB Numerous mutations in the spike protein of SARS-CoV-2 B.1.1.529 Omicron variant pose a crisis for antibody-based immunotherapies. The efficacy of emergency use authorized (EUA) antibodies that developed in early SARS-CoV-2 pandemic seems to be in flounder. In this work, we examined the Omicron variant neutralization using an early B cell antibody repertoire as well as several EUA antibodies in pseudovirus and authentic virus systems. More than half of the antibodies in the repertoire that showed good activity against WA1/2020 previously had completely lost neutralizing activity against Omicron, while antibody 8G3 from our early B cell repertoire displayed non-regressive activity. EUA antibodies Etesevimab, Casirivimab, Imdevimab and Bamlanivimab neutralized authentic WA1/2020 virus with low half maximal inhibitory concentration (IC50) values, but were entirely desensitized by Omicron. Only Sotrovimab targeting the non-ACE2 overlap epitope showed activity but with a dramatic decrease. Interestingly, antibody 8G3 efficiently neutralized Omicron in pseudovirus and authentic virus systems. 8G3 also showed excellent activity against other variants of concern (VOCs), especially more efficient against authentic Delta plus virus. Collectively, our results suggest that neutralizing antibodies with breadth remains broad neutralizing activity in tackling SARS-CoV-2 infection despite the universal evasion from EUA antibodies by Omicron variant.Competing Interest StatementThe authors have declared no competing interest.